Does oridonin inhibit pancreatic cancer cell migration and epithelial-mesenchymal transition by suppressing Wnt/β-catenin signaling pathway?
ORI can inhibit pancreatic cancer cell SW1990 migration and EMT by down-regulating Wnt/β-catenin signal transduction in vitro and in vivo. Therefore, it can be potentially and effectively used in the clinical management of pancreatic cancer.
Although the optimal model greatly increases precision, it is still inadequate for scheduling fasttrack patients, where wrong predictions for individuals can cause major problems in resource allocation.